- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06198673
A Prospective muLticEnter Registry in chrONic coronARy synDrOme (LEONARDO)
Real-world Patterns of Anti-platelet Management in Stable Angina Patients Undergoing Percutaneous Coronary Intervention
In patients with chronic coronary syndrome (CCS), clopidogrel has a class I/A indication in patients undergoing elective percutaneous coronary intervention (PCI). Although unproven, the possibility exists that clopidogrel does not yield an optimal platelet inhibition in multiple real-world scenarios that challenge current recommendations.
The aim of this prospective observational study io assess in a consecutive unselected series of patients with CCS undergoing elective PCI the frequency of the following real world clinical scenarios:
- No pretreatment at time of PCI ('naïve')
- Evidence of incomplete responsiveness to clopidogrel
- Indication to a complex PCI.
We expect to demonstrate:
- A not negligible proportion of patients with CCS are 'naïve' at time of elective PCI in clinical practice and require a rapid onset of P2Y12 inhibition.
- A substantial proportion of patients with CCS who are treated with clopidogrel prior to elective PCI have high platelet responsiveness at time of the procedure.
- A complex PCI is performed in a substantial proportion of patients with CCS.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In patients with chronic coronary syndrome (CCS), clopidogrel has a class I/A indication in patients undergoing elective percutaneous coronary intervention (PCI) (Figure 1). Initiation of oral P2Y12 inhibitors is usually delayed until the coronary anatomy is defined (Knuuti, Levine). Clopidogrel (administered as a 600 mg loading dose followed by a 75 mg maintenance dose) is the P2Y12 inhibitor of choice in CCS patients undergoing PCI (Knuuti, Levine). Also, pre-treatment with clopidogrel is currently recommended if the probability of PCI is high (II B/C). Although unproven, the possibility exists that clopidogrel does not yield an optimal platelet inhibition in multiple real-world scenarios that challenge current recommendations, as follows:
- P2Y12 inhibitors 'naive' patients with CCS who have an indication to PCI after coronary angiography might experience deferral of PCI because they are not pre-treated with clopidogrel (Selvarajah, 2021)
- Heterogeneity in individual response profiles to clopidogrel, with a considerable number of patients yielding inadequate platelet inhibitory effects, might result in increased risk of thrombotic events post-PCI (Galli). Individual responsiveness to P2Y12 inhibitors can be assessed through platelet function testing (Franchi), but its implementation in clinical practice is currently not recommended. As a consequence, a significant proportion of CCS patients are not on a fully effective dual antiplatelet therapy (DAPT) at time of PCI.
- Complex PCIs are increasingly performed in CCS patients. Complex PCI is commonly defined by any of the following characteristics: ≥ 3 drug eluting stents implanted, bifurcation PCI with 2 stents, left main coronary artery PCI, saphenous vein graft PCI, total stent length > 60 mm, or chronic total occlusion as target lesion (Figure 2). Importantly, patients who undergo complex PCI have a substantially higher ischemic risk with increased procedural complexity (Giustino, Genereaux). Preliminary observations suggest that an intensive periprocedural platelet inhibition, even on top of DAPT pretreatment, might be of benefit in stable patients undergoing percutaneous revascularization of complex lesions (Marchese).
To assess in a consecutive unselected series of patients with CCS undergoing elective PCI the frequency of the following real world clinical scenarios:
- No pretreatment at time of PCI ('naïve')
- Evidence of incomplete responsiveness to clopidogrel
- Indication to a complex PCI Consecutive patients with CCS undergoing elective PCI.
Patients will be grouped as follows:
- Pre-treatment with clopidogrel before elective PCI
- Patients receiving a clopidogrel loading at time of elective PCI in the cath lab Patients receiving cangrelor during PCI in the cath lab and then receiving a P2Y12 inhibitor afterwards
- Patients with CCS undergoing elective PCI
- Patients' written informed and privacy consent obtained before the PCI procedure
- Male or female patients 18 to 80 years old
- Assessment of response to anti-platelet agents by VerifyNowTM
- Patients with active bleeding
- Patients with hypersensitivity to any anti-platelet agents or to any of its excipients
- Known pregnancy or breast-feeding female patients > 1,000 patients Multicenter evaluation
- Pre-treatment with clopidogrel before elective PCI
- Patients receiving a clopidogrel loading at time of elective PCI in the cath lab
Patients receiving cangrelor during PCI in the cath lab and then receiving a P2Y12 inhibitor afterwards
1-year
- Frequency of 'naive' patients with CCS undergoing elective PCI
- Frequency of complex coronary intervention in patients undergoing elective PCI
- Frequency of incomplete response to clopidogrel prior to elective PCI (as assessed by VerifyNow TM)
- Frequency of the use of periprocedural i.v. cangrelor
- Frequency of the use of glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors
- Frequency of the use of clopidogrel, ticagrelor or prasugrel loading dose
- Mode of administration of oral P2Y12 inhibitors (crushed)
- Incidence of post-PCI ischemic complications
- Incidence of any post-PCI bleeding according to the Bleeding Academic Research Consortium [BARC] criteria
- Incidence of major adverse cardiac events (MACE) - MACE will comprise any of the following events: death, myocardial infarction (MI), ischemia-driven revascularisation (IDR) and stent thrombosis (ST)
- Enrolment phase (1 year)
- Follow-up: 1-year
The study will be conducted in accordance with the Declaration of Helsinki on ethical principles for medical research involving human subjects.
Informed consent to be included in this survey is mandatory for collecting individual data and must be obtained from all subjects and/or their legal representative(s) as per local regulations.
We expect to demonstrate:
- A not negligible proportion of patients with CCS are 'naïve' at time of elective PCI in clinical practice and require a rapid onset of P2Y12 inhibition.
- A substantial proportion of patients with CCS who are treated with clopidogrel prior to elective PCI have high platelet responsiveness at time of the procedure.
- A complex PCI is performed in a substantial proportion of patients with CCS.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Francesco Pelliccia, MD
- Phone Number: 123 +394997
- Email: f.pelliccia@mclink.it
Study Contact Backup
- Name: Carlo Gaudio, MD
- Phone Number: 123 +394997
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Consecutive patients with CCS undergoing elective PCI.
Patients will be grouped as follows:
- Pre-treatment with clopidogrel before elective PCI
- Patients receiving a clopidogrel loading at time of elective PCI in the cath lab Patients receiving cangrelor during PCI in the cath lab and then receiving a P2Y12 inhibitor afterwards
Description
Inclusion Criteria:
- Patients with CCS undergoing elective PCI
- Patients' written informed and privacy consent obtained before the PCI procedure
- Male or female patients 18 to 80 years old
- Assessment of response to anti-platelet agents by VerifyNowTM
Exclusion Criteria:
- Patients with active bleeding
- Patients with hypersensitivity to any anti-platelet agents or to any of its excipients
- Known pregnancy or breast-feeding female patients
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of 'naive' patients with CCS undergoing elective PCI
Time Frame: up to 12 months
|
Number of 'naive' patients with CCS undergoing elective PCI
|
up to 12 months
|
Frequency of complex coronary intervention in patients undergoing elective PCI
Time Frame: up to 12 months
|
Number of complex coronary intervention in patients undergoing elective PCI
|
up to 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Francesco Pelliccia, MD, University Sapienza
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023/D/18122023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Antiplatelet Agents
-
Josep Rodes-CabauRecruitingIschemic Stroke | Patent Foramen Ovale | Bleeding UlcerCanada
-
Institute of Cardiology, Warsaw, PolandMedical Research Agency, PolandRecruitingAtrial FibrillationPoland
-
National Institute of Cardiology, Warsaw, PolandMedical Research Agency, PolandRecruitingAtrial FibrillationPoland
-
Centre Hospitalier Universitaire de Saint EtienneNot yet recruiting
-
Sichuan Provincial People's HospitalRecruitingIschemic Stroke | Antiplatelet DrugChina
-
China National Center for Cardiovascular DiseasesRecruitingMyocardial Infarction | Myocardial Ischemia | Coronary Artery Disease | Bleeding | Angina Pectoris | Dual Antiplatelet Therapy | Coronary Artery Bypass GraftingChina
-
State University of New York - Upstate Medical...CompletedIschemic Stroke | TIAUnited States
-
Icahn School of Medicine at Mount SinaiNational Heart, Lung, and Blood Institute (NHLBI); Vanderbilt University Medical...RecruitingStroke | Atrial Fibrillation | BleedingUnited States, United Kingdom, Canada, Germany
-
Beijing Tiantan HospitalBeijing Friendship Hospital; RenJi Hospital; Qilu Hospital of Shandong University and other collaboratorsRecruitingSpontaneous Intracerebral HemorrhageChina
-
Assiut UniversityCompletedCoronary Artery Disease | EctasiaEgypt